Menu

News

Home » NewsPage 3
Timber Pharmaceuticals Announces Positive End-of-Phase 2 Meeting with FDA for TMB-001 in Moderate to Severe Congenital Ichthyosis
Thu February 3, 2022 | 11:44 pm
Continue Reading
PaxMedica Plans to Initiate Phase 1B Study for PAX-101 in Patients with Long COVID-19 Syndrome
Fri January 7, 2022 | 07:25 am
Continue Reading
SPARC Licenses Development and Commercialization Rights of PDP-716 and SDN-037 to Visiox Pharma
Wed December 8, 2021 | 06:28 pm
Continue Reading
Timber Pharmaceuticals to Host Conference Call Discussing Positive Topline Results from Phase 2b CONTROL Study of Congenital Ichthyosis for Lead Asset, TMB-001
Wed November 17, 2021 | 08:00 am
Continue Reading
Timber Pharmaceuticals Announces Closing of $15 Million Public Offering
Fri November 5, 2021 | 08:30 am
Continue Reading
PaxMedica selected by American Academy of Child and Adolescent Psychiatry (AACAP) to Present Data from its Recent Phase 2 Trial of PAX-101 (IV suramin) in Children with Autism Spectrum Disorder (ASD) in the Research Pipeline Program
Thu August 19, 2021 | 06:16 pm
Continue Reading
PaxMedica Announces Positive Results from Phase 2 Trial of PAX-101 (IV suramin) in Children with Autism Spectrum Disorder (ASD)
Tue February 9, 2021 | 06:23 pm
Continue Reading
1 2 3
Set your categories menu in Header builder -> Mobile -> Mobile menu element -> Show/Hide -> Choose menu